Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at Oppenheimer

Astria Therapeutics (NASDAQ:ATXS) had its price target lifted by Oppenheimer from $26.00 to $28.00 in a report issued on Thursday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other equities research analysts also recently commented on the company. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Friday, September 27th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 7.1 %

Shares of Astria Therapeutics stock opened at $9.37 on Thursday. The business has a fifty day simple moving average of $11.40 and a two-hundred day simple moving average of $10.62. The firm has a market capitalization of $528.66 million, a P/E ratio of -4.48 and a beta of 0.71. Astria Therapeutics has a 12 month low of $4.26 and a 12 month high of $16.90.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATXS. RA Capital Management L.P. purchased a new stake in shares of Astria Therapeutics in the first quarter valued at approximately $62,115,000. FMR LLC lifted its stake in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Artal Group S.A. bought a new stake in Astria Therapeutics during the first quarter valued at about $12,445,000. Vestal Point Capital LP boosted its holdings in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Astria Therapeutics during the second quarter valued at approximately $6,142,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.